APAC Nucleic Acid Labelling Market

APAC Nucleic Acid Labelling Market Size (2022 to 2027)

The Nucleic Acid Labelling Market size in the Asia Pacific was valued at USD 242.99 Million in 2022. It is further projected to be growing at a CAGR of 9.9% and worth USD 389.56 Million by 2027.

Nucleic Acid Labelling has many applications in the fields of drug discovery and identification of new diseases. DNA and RNA are the information-carrying Nucleic acids that are of great significance for protein synthesis. They can be labeled with tags that assist in detection and purification processes. One of the labeling techniques is Nick Translation. Some of the nucleotides of a DNA sequence with their labeled analogs create a tagged DNA sequence used to probe fluorescent in situ hybridization blotting techniques. It can also be used for radiolabelling. DNA labeling has various applications in diagnosis and biotechnology.

The market's primary driving forces are increasing funding for R&D in genomics and disease diagnosis, increasing expenditure for health care, and increasing demand for personalized healthcare.

But, factors like expensive processing techniques and lack of skilled professionals are likely to hinder the market's growth.

This research report on the Asia Pacific Nucleic Acid Labelling Market has been segmented and sub-segmented into the following categories:

By Product: 

• Reagents and Kits
• Services

By Labelling Technique: 

• PCR
• Nick Translation
• Random Primer
• In-Vitro Transcription
• Reverse Transcription

By Application: 

• DNA Sequencing
• PCR
• Fluorescence in Situ Hybridization (FISH)
• Microarrays
• Blotting
• In-Situ Hybridization

By End Users: 

• Diagnostic Centres
• Research Centres
• Hospitals

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, In Asia Pacific (APAC) Nucleic Acid Labelling Market, the rise in personalized medicine and the identification of GMOs and therapeutic will drive this market area's growth during the forecast period. It is further anticipated that emerging markets, such as China and Brazil, will achieve significant growth by the end of the forecast period.

The Asia Pacific is attributed to the prolongation of chronic diseases such as cancer, the aging of the population, the growing demand for targeted, personalized medicine, and aggressive government initiatives. In recent years, the government has launched initiatives that complement the APAC nucleic acid labeling market's growth. For example, the Precision Medicine Program's introduction in 2015 revolutionized the treatment of chronic diseases, which has accelerated nucleic acid labeling and acceptance in the region. India is foreseen to be another promising area in the APAC nucleic acid labeling market.

Companies playing a dominating role in the Asia Pacific Nucleic Acid Labelling Market include Thermo Fisher Scientific, New England Biolabs, PerkinElmer, F. Hoffmann La-Roche AG, General Electric Company, Merck KGaA, Enzo Biochem, Promega Corporation, Vector Laboratories, and Agilent Technologies.